Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: A Phase II, randomized study

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 611-617

  Zarogoulidis, Konstantinos ^a   Ziogas, Eftimios ^a   Boutsikou, Efimia ^a   Zarogoulidis, Paul ^a,b   Darwiche, Kaid ^b   Kontakiotis, Theodoros ^a   Tsakiridis, Kosmas ^c   Porpodis, Konstantinos ^a   Latsios, Dimitrios ^a   Chatzizisi, Olga ^a   Karapantzos, Ilias ^c   Li, Qiang ^d   Kyriazis, Georgios ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b RUHRLANDKLINIK   (Germany)

^c Saint Luke Private Hospital   (Greece)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunomodifiers; Interferon; Lung cancer; SCLC

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; GAMMA INTERFERON;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; DRUG FEVER; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; SMALL CELL LUNG CARCINOMA;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-GAMMA; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 84880706908     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S43184     Document Type: Article

References (30)

1. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 1997;80(1):42-49.
2. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802-807.
3. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767-1771.
4. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787): 442-447.
5. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol. 1998;10(5):383-390.
6. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 15 1998;58(12):2489-2499.
7. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem. 1992;267(8):5017-5020.
8. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg. 1993;28(10):1253-1257.
9. Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1985:251-282.
10. Kurzrock R, Rosenblum MG, Quesada JR, Sherwin SA, Itri LM, Gutterman JU. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. J Clin Oncol. 1986;4(11):1677-1683.
11. Hand A, Pelin K, Halme M, et al. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines. Anticancer Drugs. 1993;4(3):365-368.
12. Zarogoulidis P, Kioumis I, Papanas N, et al. The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in non-responding tuberculosis and diabetes mellitus: a case report and review of the literature. J Chemother. 2012;24(3):173-177.
13. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990;50(12):3473-3486.
14. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol. 1983;10(3):161-166.
15. Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR, Smyth JF. Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. Cancer Res. 1986;46(10):4916-4920.
16. Bonnem EM. Alfa interferon: combinations with other antineoplastic modalities. Semin Oncol. 1987;14(2 Suppl 2):48-60.
17. Mattson K, Nea A. Concomitant chemotherapy (CT) and interferon-alpha (IFN alpha) for SCLC. Proc Am Soc Clin Oncol. 1995;14:370.
18. Zarogoulidis K, Ziogas E, Papagiannis A, et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer. 1996;15(2):197-205.
19. Thatcher N, Cerny T, Stout R, et al. Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer. 1987;60(10):2382-2387.
20. Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol. 2005;23(33): 8371-8379.
21. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-1698.
22. McCracken JD, Janaki LM, Crowley JJ, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol. 1990;8(5):892-898.
23. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 1994;12(11):2321-2326.
24. Pohl WR. Interferon therapy of the lung and locoregional therapy in pulmology. Wien Med Wochenschr. 1993;143(16-17):450-454.
25. Malmberg KJ, Levitsky V, Norell H, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest. 2002;110(10):1515-1523.
26. Tanio Y, Watanabe M, Osaki T, et al. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity. Jpn J Cancer Res. 1992;83(7):736-745.
27. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994;91(4):1198-1205.
28. Wagstaff J, Smith D, Nelmes P, Loynds P, Crowther D. A phase I study of recombinant interferon gamma administered by sc injection three times per week in patients with solid tumours. Cancer Immunol Immunother. 1987;25(1):54-58.
29. Fischer JR, Schindel M, Stein N, et al. Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol. 1995;6(9):921-926.
30. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013 May;63(3):151-66.